Patents by Inventor Seth Porter

Seth Porter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20220151581
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Application
    Filed: January 27, 2022
    Publication date: May 19, 2022
    Applicant: FibroGen, Inc.
    Inventors: Seth PORTER, John L STAUFFER
  • METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20200113533
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 16, 2020
    Applicant: FibroGen, Inc.
    Inventors: Seth PORTER, John L. Stauffer
  • Methods for treating idiopathic pulmonary fibrosis
    Patent number: 10555713
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: February 11, 2020
    Assignee: FIBROGEN, INC
    Inventors: Seth Porter, John L. Stauffer
  • COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT
    Publication number: 20190201354
    Abstract: The invention provides extended release amantadine compositions for once daily administration of amantadine to a subject.
    Type: Application
    Filed: March 7, 2019
    Publication date: July 4, 2019
    Inventors: Gregory T. WENT, Timothy J. FULTZ, Laurence R. MEYERSON, Seth PORTER, Timothy S. BURKOTH
  • METHODS OF TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20190127456
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering an anti-CTGF antibody. In particular, the treatment methods provided avoid toxicities associated with approved therapies and also avoid the attenuation of the efficacy of an anti-CTGF antibody caused by these approved therapies.
    Type: Application
    Filed: September 14, 2018
    Publication date: May 2, 2019
    Applicant: FibroGen, Inc.
    Inventors: Seth Porter, Kenneth E. Lipson, Eduard Gorina de Travy, Kin-Hung Peony Yu
  • COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT
    Publication number: 20190008799
    Abstract: The invention provides extended release amantadine compositions for once daily administration of amantadine to a subject.
    Type: Application
    Filed: February 2, 2018
    Publication date: January 10, 2019
    Inventors: Gregory T. WENT, Timothy J. FULTZ, Laurence R. MEYERSON, Seth PORTER, Timothy S. BURKOTH
  • METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20180310906
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 1, 2018
    Applicant: FibroGen, Inc.
    Inventors: Seth Porter, John L. Stauffer
  • Methods for treating idiopathic pulmonary fibrosis
    Patent number: 10039515
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: August 7, 2018
    Assignee: FIBROGEN, INC.
    Inventors: Seth Porter, John L Stauffer
  • Composition for Administering an NMDA Receptor Antagonist to a Subject
    Publication number: 20170281565
    Abstract: The invention provides extended release amantadine compositions for once daily administration of amantadine to a subject.
    Type: Application
    Filed: November 15, 2016
    Publication date: October 5, 2017
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson, Seth Porter, Timothy S. Burkoth
  • Composition for Administering an NMDA Receptor Antagonist to a Subject
    Publication number: 20170056340
    Abstract: The invention provides extended release amantadine compositions for once daily administration of amantadine to a subject.
    Type: Application
    Filed: April 1, 2016
    Publication date: March 2, 2017
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson, Seth Porter, Timothy S. Burkoth
  • METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20170027535
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Application
    Filed: September 13, 2016
    Publication date: February 2, 2017
    Applicant: FibroGen, Inc.
    Inventors: SETH PORTER, John L. Stauffer
  • Methods for treating idiopathic pulmonary fibrosis
    Patent number: 9480449
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IFF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 1, 2016
    Assignee: FIBROGEN, INC.
    Inventors: Seth Porter, John L Stauffer
  • Therapeutic method
    Patent number: 9102721
    Abstract: Described herein are methods for treating connective tissue growth factor (CTGF)-associated cancers, including pancreatic cancer, using an anti-CTGF antibody. Increased antibody exposure was demonstrated to improve patient outcome.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: August 11, 2015
    Assignee: FibRoGen, Inc.
    Inventors: Thomas B. Neff, Seth Porter, Frank H. Valone
  • METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20150086483
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IFF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 26, 2015
    Applicant: FibroGen, Inc.
    Inventors: Seth Porter, John L. Stauffer
  • Composition and method for treating neurological disease
    Patent number: 8987333
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: March 24, 2015
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
    Publication number: 20140356425
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: August 4, 2014
    Publication date: December 4, 2014
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Composition and method for treating neurological disease
    Patent number: 8895614
    Abstract: A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: November 25, 2014
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Composition and method for treating neurological disease
    Patent number: 8895617
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: November 25, 2014
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Composition and method for treating neurological disease
    Patent number: 8895616
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: November 25, 2014
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Composition and method for treating neurological disease
    Patent number: 8895618
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: November 25, 2014
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth